Professor the Lord Ajay Kakkar, Chair, UCLPartners

Professor Sir David Fish, Managing Director, UCLPartners

Dr Charlie Davie, Director of UCLPartners AHSN

Clare Panniker, Chief Executive, Basildon and Thurrock University Hospitals NHS Foundation Trust

UCLPartners academic health science partnership

2

11 higher education institutesand research networks

26 boroughs and local councils

23 healthcare organisations acute and mental health trusts; community providers

20 Clinical Commissioning Groups (CCGs)

What is UCLPartners?

Industry partnerships in research and translation of innovation into health and wealth

Six million population

3

Local Enterprise Partnership – key challenge

• Working with the London Enterprise Panel, established by the Mayor of London

• Professor Stephen Caddick, Vice Provost (Enterprise), UCL, is the only academic representative on the Panel

• Key challenges of the panel: to compete with Boston and San Francisco; improve access to the NHS market to increase venture capital

• How UCLPartners is contributing: working with industry to co-create technology and devices; creating long-term partnerships with industry and giving confidence to entrepreneurs, e.g. through new business models andprocurement initiatives

• Other areas of joint working: MedCity, Care City, London Health Commission, three London AHSNs and preparing to enable the success of the Francis Crick Institute

4

Bringing together formal designations under one umbrella and working with partners to:

• Discover new treatments and methods for

improving health

• Develop discoveries through clinical trials

• Implement changes at scale and pace across the

partnership

• Evaluate how the system is working and what can

be done next

• Educate the workforce and develop capabilities

• Use information to its best effect throughout

the system

Information

Education

Population

Defragmenting the pathway – an integrated journey to transform healthcare through innovation into practice

5

Example: Use of Natalizumab for multiple sclerosis

DISCOVERY

Surrogate markers and

proof of concept studies

CLINICAL TRIALS

Phase 1-3 clinical trials

IMPLEMENTATION

Treatment received by

112,000 patients

EVALUATION

“Real world” evaluation

clinical impact and efficacy

CAPABILITY

Educational publications and clinical training

Relationships Patient pull Alignment Outcomes

• Health improvement: 66% reduction in relapse, 50% reduction in relapse-related disability• Example of potential for economic gain: Natalizumab sales generated $1.6bn for Biogen in 2012

6

UCLPartners turnover

Value add to partner organisations

Value add to population

Business model

7

Academic medical centre model for the AHSC

GOSH & UCL Child Health

QUEEN SQUARE HOUSE

BARTS CARDIOVASCULAR

CENTRE FOR CHILDREN’S RARE

DISEASE RESEARCH

INSTITUTE OF IMMUNITY & TRANSPLANTATION

MOORFIELDS / INSTITUTE OF OPHTHALMOLOGY

UCLPartners

UCLH CANCER CENTREUCL CANCER INSTITUTE

8

Population reach and impact through the AHSN

nested in

AHSN

AHSC PARTNERS

9

Specialist cancer and cardiac services

Barts Heart Centre Cancer Centre at UCLH

Benefits of improvements along whole pathway of care and to health economy: • 1,200 lives saved per year• Net present value gain of £94m• Globally competitive life sciences• International private practice

10

Clinical trials

0

5,000

10,000

15,000

20,000

25,000

HarmonisationImpact of harmonisation on approval times: median permission time

North Thames Clinical Research Networkranks top nationally for recruitment (April to Aug 2014)

11

Quintiles Prime Site far exceeds the company recruitment target

UCLPartners is the highest performer for Quintiles in Europe

12

Investing in genomics

NHS England / GEL

Genomics Executive Board

Genomics Operations Team

GOSHLead trust

UCLH Moorfields NWLH RFH BH

UCLPartners Executive

(Partnership Board) then to

UCLPartners Board

Proposed governance structure of UCLPartners North West Genomic Medicine Centre

0

200

400

600

800

1000

1200

1400

UCLPartners Cambridge and NewcastleUniversities

DNA samples provided in Genomics England Rare Diseases Pilot (3 sites)

1300

700

• UCLPartners, Cambridge and Newcastle Universities were the original partners in the Genomics England Rare Diseases Pilot

• UCLPartners contributes 68% of the national sample

13

Supporting people in London’s growth boroughs

In Newham, UCLPartners is supporting:

• Academic development of local people with £2m investment from Newham CCG and UCLPartners support to assist in the transformation of primary care

• Establishment of an academic centre for health improvement science at the Sir Ludwig Guttmann Centre (the Olympic Medical Centre): potential scaling across London

• Improvements in local health priorities through programmes on diabetes, cardiovascular disease, low birth weight babies and quality and capacity in primary care with a focus on health behaviours and inequalities

• Children’s resilience through a mental health programme for young people, which has won £500k Big Lottery bid (with potential for £10m over five years)

• University development in the Olympic park in potential collaboration with pharma

14

Supporting people in outer north east London

• Supporting an innovative pilot primary care practice in Barking, Havering and Redbridge – delivering what matters most to 1,000 patients with most complex care needs

• Care City – supporting local training and apprenticeships, informatics and industry

• Life Study – largest ever cohort study of 80,000 children from birth to adulthood at Queen’s and King George hospitals, collaborating with CCG and other care providers

15

Better health and

wealth

Improving education & employment outcomes in adolescents

Supporting workplace health and wellbeing

Getting people back

to work

Mental health issues affect 1 in 4 people in England and have implications for employment

Individual productivity

UK plc

Business productivity

16

More effective and efficient care

for patients

New business model – shared risk, co-created, implemented

One-off seed funding of £30,000 to Concentra

£30,000 to purchase platform

£10,000 profit

If this was rolled out across all local authorities

total savings could be £15.2m plus recurrent

annual savings of £11.5m

UCLPartners and SME

(Concentra)

Client

Investment Value

£100,000 saving (based on cost of

alternative platforms)

37.5% profit to Concentra

37.5% profit to UCLPartners

25% for product maintenance

Recurring staff cost savings of

£76k pa

Costs of £20,000 per

product

17

Innovation in informatics and data science

Our approach to informatics

• Connect the existing strengths the partnership has

• Support partners to create a model of innovation that will save lives, transform services for patients and create value for organisations

• Develop educational programmes for our clinical workforce

• Expand industry partnerships

Encouraging systemic innovation

• UCLPartners is co-applicant and core partner of theonly UK bid for the €600 million Knowledge Innovation Community in Healthy Living and Active Ageing – integrating Education, Research and Business

• Aiming to create sustainable health systems across Europe, ready to tackle the challenges of our ageing population

18

Quality and safety

• Value-based strategy based on Michael Porter’s work• Patient Safety Collaboratives• Sign up to Safety campaign• Partnership programmes are saving lives:

• Collaboration across 15 trusts is reducing cardiac arrests in hospitals by up to 50% by identifying and responding to deteriorating patients

19

•Clinical Effectiveness Group model = 10% OACs over 2 yrs.

Diffused to Camden in 6

months

•9% OACs

•Avoided 5 strokes pa

•Saves £60k pa NHS costs

Stage 2 bid for £500k to take to four more

CCGs •>10% OACs

•Avoid >50 strokes pa

•Saves >£600k pa NHS costs

•Saves >£1m pa social care costs

UCLPartners diffuses

across the partnership

•Avoid 700 strokes pa

•Saves £8.4m pa NHS costs

•Saves £16m pa indirect social care costs

Estimated impact

UCLPartners wide

Atrial fibrillation – working together to save and improve lives

Pharma

NICEMed Tech CCGs

SCNsProviders Universities

Patient groups

Atrial fibrillation community of interest

Local authorityAHSNs

NIC

CEG

Stroke avoidance savings ref: Hunter et al 2013

20

Quality and value

We must replace today’s fragmented system, in which every local provider offers a full range of services, with a system in which services for particular medical conditions are concentrated in health-delivery organizations and in the right locations to deliver high-value care.

Prof Michael Porter, HarvardUCLPartners conference, City Hall, 2012